Overview of Registered Trials on the Chinese Clinical Trial Registry (Chictr)
Junqi Liu,Runze Zhou,Narasimha M. Beeraka,Olga A. Sukocheva,Baosheng Li,Junjie Wang,Xiaoyan Wang,Ruixia Song,Yihan Zhou,Nannan Xue,Shijie Li,Xiang Zhao,Chunying Liu,Song He,Kuo Chen,Di Zhao,Ruitai Fan
DOI: https://doi.org/10.2139/ssrn.3988012
2021-01-01
SSRN Electronic Journal
Abstract:Background: Clinical trial registry (CTR) data analysis provides reliable background and insights for large-scale development of health regulations and promotion of transparency in clinical trial support. Chinese Clinical Trial Registry (ChiCTR) platform, the third largest CTR in the world, was used in this study for analysis of the data collected during the last 13 years in China.Methods: A multi-dimensional grouping analysis was conducted to estimate trends in annual trial registration, geographical distribution, sources of funding, targeted diseases, and trial types. We have analysed all available clinical trial records (over 30,000) registered on ChiCTR platform from 2007 to 2020 via ChiCTR.gov.Results: A steady upward trend in clinical trial registrations was observed from 2008 to 2017. The year-on-year (yoy%) growth of registration was the highest in 2014 and 2018. Public funding represented the largest category of funding sources in Chinese healthcare system. The top five ChiCTR registration sites for all disease types were highly populated urban regions of China, including Shanghai, Beijing, Guangdong, Sichuan, and Jiangsu. Trials targeting neoplastic diseases accounted for the largest portion of registrations, followed by cardio/cerebrovascular and orthopaedic diseases-related trials.Conclusions: In China, research on oncological and cardiovascular diseases receives the highest share of national public funding for medical research. Publicly funded trials occupied a major segment in the registry. The analysed records reflect escalation of clinical research activities in China and distribution of public funding resources towards highly populated areas with the highest incidence of oncological and cardiovascular diseases.Funding Information: This study was supported by National Natural Science Foundation of China (No. 81703158).Declaration of Interests The authors declare no conflict of interest.